Please ensure Javascript is enabled for purposes of website accessibility

Here's Why HEXO Stock Jumped Today

By Cory Renauer – Updated Apr 17, 2019 at 5:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A big investment bank finally weighed in on marijuana stocks, and it likes what it sees in HEXO.

What happened

Shares of HEXO Corp. (HEXO 1.24%), a licensed Canadian cannabis producer, are on the move, thanks to a positive outlook from an analyst at Bank of America. Investors encouraged by the investment bank's optimism pushed the stock 11.5% higher on Wednesday.

So what

Bank of America initiated coverage of HEXO with a buy recommendation and a $10 price target, which was 66% above the stock's closing price yesterday. The analyst, Christopher Carey, went a step further and named the Quebec-based company a "top pick in cannabis."

A doctor holding a bag of marijuana buds in one hand and a handful of green capsules in the other

Image source: Getty Images.

At the top of Carey's list of reasons to like HEXO is the stock's relatively low valuation. The cannabis producer's market cap has risen to $1.4 billion at recent prices, which seems like a lot for a company with annualized revenue of just $40.1 million. (Both figures are in U.S. dollars.) While that's a nosebleed valuation in any other industry, it's still low enough to make HEXO one of the most reasonably priced Canadian cannabis companies trading on U.S. exchanges.

Now what

HEXO has supply agreements with four provincial governments, one of which could be worth 1 billion Canadian dollars in revenue over the next several years.

Looking beyond Canada's borders, HEXO is taking steps to become an international player in a global cannabis market expected to reach CA$630 billion annually. To this end, the company is developing a 350,000-square-foot facility in Greece, which it hopes will soon be able to supply medical marijuana markets now opening up in the EU.

HEXO finished January with CA$224 million in working capital, after operations lost CA$6.9 million during the three months ended January. If the company remains disciplined, it can probably begin producing positive cash flow before resorting to another dilutive share offering.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends HEXO. The Motley Fool has a disclosure policy.

Stocks Mentioned

Hexo Stock Quote
$0.16 (1.24%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.